Boxer Capital Ups Tango Therapeutics Stake

Ticker: TNGX · Form: SC 13D/A · Filed: Oct 28, 2024 · CIK: 1819133

Sentiment: neutral

Topics: ownership-change, activist-filing, pharmaceuticals

Related Tickers: TNGX

TL;DR

Boxer Capital now owns 11.6% of Tango Therapeutics after filing an amendment.

AI Summary

Boxer Capital Management, LLC, along with affiliated entities, has amended its Schedule 13D filing concerning Tango Therapeutics, Inc. as of October 28, 2024. The filing indicates a change in beneficial ownership, with Boxer Capital Management, LLC now holding 10,170,141 shares, representing approximately 11.6% of the outstanding common stock. This amendment reflects adjustments to their holdings and potentially their strategy regarding Tango Therapeutics.

Why It Matters

This filing signals a significant ownership stake by Boxer Capital, potentially influencing Tango Therapeutics' strategic decisions and future direction.

Risk Assessment

Risk Level: medium — Changes in significant beneficial ownership can indicate shifts in investor sentiment or strategy, which may impact the stock's volatility.

Key Numbers

Key Players & Entities

FAQ

What specific event or change prompted this amendment to the Schedule 13D filing?

The filing does not explicitly state a single event but indicates a change in beneficial ownership as of October 28, 2024, with Boxer Capital Management, LLC now holding 10,170,141 shares.

What is the total number of Tango Therapeutics shares outstanding as of this filing?

The filing states that Boxer Capital Management, LLC holds 10,170,141 shares, representing approximately 11.6% of the outstanding common stock. This implies a total of roughly 87,673,630 shares outstanding (10,170,141 / 0.116).

Who are the other named group members associated with Boxer Capital Management, LLC in this filing?

The other named group members are Aaron I. Davis, BCTG Holdings, LLC, and MVA Investors, LLC.

What is the business address and phone number for Tango Therapeutics, Inc.?

The business address for Tango Therapeutics, Inc. is 201 Brookline Avenue, Suite 901, Boston, MA 02215, and the business phone number is (857) 320-4900.

What was Tango Therapeutics' former company name and when did the name change occur?

Tango Therapeutics, Inc. was formerly known as BCTG Acquisition Corp., and the date of the name change was July 23, 2020.

Filing Stats: 1,563 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-10-28 09:22:40

Key Financial Figures

Filing Documents

is hereby amended to correct that Mr. Davis is the Managing Member of BCM

Item 2 is hereby amended to correct that Mr. Davis is the Managing Member of BCM. Item 5. Interest in Securities of the Issuer. Items 5(a) and (b) are hereby amended and restated to read as follows: (a) (b) For information regarding beneficial ownership, see the information presented on the cover pages. All percentages are based on 107,176,965 shares of the Issuer's Common Stock outstanding, which is (i) 107,144,465 shares of the Issuer's Common Stock outstanding as of August 1, 2024 as set forth in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 7, 2024, plus (ii) 32,500 shares of Common Stock subject to options to purchase shares of Common Stock, held by Mr. Davis, exercisable in the next 60 days.

(c) is hereby supplemented by the addition of the following

Item 5(c) is hereby supplemented by the addition of the following: BCM caused an account under its management to sell shares of the Issuer's Common Stock in the open market for cash on October 21, 2024, October 22, 2024 and October 25, 2024, in each case in the number and at the average price disclosed in a filing on Form 4. Item 7. Material to be Filed as Exhibits.

is hereby amended by the addition of the following

Item 7 is hereby amended by the addition of the following: Exhibit No. Description Exhibit 4 Joint Filing Agreement, dated October 28, 2024, among BCTG Holdings, MVA Investors, Mr. Davis and BCM.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 28, 2024 BCTG HOLDINGS, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Manager MVA INVESTORS, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Authorized Signatory AARON I. DAVIS /s/ Aaron I. Davis Aaron I. Davis, Individually BOXER CAPITAL MANAGEMENT, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Managing Member JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Tango Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument. Dated: October 28, 2024. BCTG HOLDINGS, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Manager MVA INVESTORS, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Authorized Signatory AARON I. DAVIS /s/ Aaron I. Davis Aaron I. Davis, Individually BOXER CAPITAL MANAGEMENT, LLC By: /s/ Aaron I. Davis Name: Aaron I. Davis Title: Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on Read The Filing